产品名称 | lulizumab pegol |
---|
CAS编号和信息 | Ab175587 |
---|
IMGT/mAb-DB | 499 |
---|---|
Wikipedia | Lulizumab_pegol |
Target ID | 2863 | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
名称 | CD28 | ||||||||||||||||||||||||
缩写名 | SHP2 | ||||||||||||||||||||||||
家族 | Other immune checkpoint proteins | ||||||||||||||||||||||||
别名 | KCa2.1 | ||||||||||||||||||||||||
基因和蛋白信息 |
|
||||||||||||||||||||||||
RefSeq Protein | NP_006130 (Hs) , NP_031668 (Mm) , NP_037253 (Rn) | ||||||||||||||||||||||||
Protein GI | 5453611 (Hs) , 161484597 (Mm) , 6978625 (Rn) | ||||||||||||||||||||||||
RefSeq Nucleotide | NM_006139 (Hs) , NM_007642 (Mm) , NM_013121 (Rn) | ||||||||||||||||||||||||
UniProtKB | P10747 (Hs) , P31041 (Mm) , P31042 (Rn) | ||||||||||||||||||||||||
OMIM | 186760 (Hs) | ||||||||||||||||||||||||
Entrez Gene | 940 (Hs) , 12487 (Mm) , 25660 (Rn) | ||||||||||||||||||||||||
Ensembl Gene | ENSG00000178562 (Hs) , ENSMUSG00000026012 (Mm) , ENSRNOG00000010283 (Rn) | ||||||||||||||||||||||||
CATH/Gene3D | 2.60.40.10 (N/A) | ||||||||||||||||||||||||
ChEMBL Target | CHEMBL5191 (Hs) |
Ligand ID | 8460 |
---|---|
名称 | lulizumab pegol |
别名 | BMS-931699 |
类别 | Antibody |
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
评价 |
Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody Peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
配体家族 | Immune checkpoint modulators |
单字母多肽序列 | |
三字母多肽序列 | |
翻译后修饰 | |
化学修饰 |
1. Howland KC, Ausubel LJ, London CA, Abbas AK. (2000) The roles of CD28 and CD40 ligand in T cell activation and tolerance.. J Immunol, 164 (9): (4465-70). [PMID:10779746] |
2. Pisal DS, Kosloski MP, Balu-Iyer SV. (2010) Delivery of therapeutic proteins.. J Pharm Sci, 99 (6): (2557-75). [PMID:20049941] |
3. Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H et al.. (2013) A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.. J Immunol, 191 (9): (4599-610). [PMID:24081989] |
4. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. (1989) CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.. Proc Natl Acad Sci USA, 86 (4): (1333-7). [PMID:2465550] |